Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 13Neuroblastoma 4von Hippel-Lindau Disease 3Paraganglioma 3Carcinoid Tumor 3Pheochromocytoma 2Multiple Endocrine Neoplasia Type 1 2Medulloblastoma 2Gastro-enteropancreatic neuroendocrine tumor 2Somatostatinoma 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Meningioma 1Hypertension 1

Interventions

Temozolomide 2Capecitabine 2veliparib 1pentetreotide 1motesanib diphosphate 1gallium Ga 68 dotatate 1batifiban 1Sorafenib 1Oxaliplatin 1Octreotide 1Magnetic Resonance Spectroscopy 1Leucovorin 1Fluorouracil 1Bevacizumab 111-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Somatostatinoma × gallium Ga 68 dotatate × NET × Clear all
NCT01869725 2021-09-22

Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT

University of Iowa

Phase 2 Completed
68 enrolled 8 charts
CNSEndocrineNET

Medulloblastoma, Neuroblastoma, Somatostatinoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡